Application of novel HDAC inhibitor LAQ824 to drug for treating diffuse largeB-cell lymphoma

Abstract

The invention provides application of novel HDAC inhibitor LAQ824 to the treatment of diffuse largeB-cell lymphoma. LAQ824 can effectively kill DLBCL cells in a concentration range of 0-0.1[mu]M and exhibits a drug concentration-dependence. By inhibiting the expression of Chk2 in the DLBCL cells, the repair of Chk2 to DNA damage of tumor cells can be weaken, the sensitivity of the cells to drugs is increased, and the DLBCL cell apoptosis is induced.

Description

technical field [0001] The invention relates to the field of molecular therapy, in particular to the application of a novel HDAC inhibitor LAQ824 in the treatment of diffuse large B-cell lymphoma. Background technique [0002] Lymphoma is the most common hematologic malignancy, among which diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, accounting for about 30%-50% of all lymphomas . DLBCL is a highly aggressive and heterogeneous group of diseases that differ in genetic alterations, clinical features, morphological manifestations, treatment response, and prognosis. According to gene expression profiling analysis, DLBCL can be divided into two main types: germinal center B-cell-like lymphoma (GCB type) and activated B-cell-like lymphoma (ABC type); in addition, there are some third types of DLBCL whose cell origin cannot be determined . Immunohistochemistry divides DLBCL into two types: GCB and non-GCB (including ABC and type III). [0003] ...

AI Technical Summary

Problems solved by technology

Although various targeted drugs and immunotherapy have provided more choices for DLBCL patients, some DLBCL patients still have drug resistance, relapse, and refractory

Images